Pharmacokinetic drug interactions with oral contraceptives

DJ Back, MLE Orme - Clinical pharmacokinetics, 1990 - Springer
Oral contraceptive steroids are used by an estimated 60 to 70 million women worldwide.
Over the past 20 years there have been both case reports and clinical studies on the topic of …

Protein binding in antiretroviral therapies

M Boffito, DJ Back, TF Blaschke… - AIDS research and …, 2003 - liebertpub.com
There is marked variability in the extent to which the three classes of antiretroviral (ARV)
drugs bind to plasma proteins (<5 to >99%). Protease inhibitors (PIs), with the exception of …

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

J Fellay, C Marzolini, ER Meaden, DJ Back, T Buclin… - The Lancet, 2002 - thelancet.com
Background HIV-1-infected patients vary considerably by their response to antiretroviral
treatment, drug concentrations in plasma, toxic events, and rate of immune recovery. This …

Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive‐drug interactions with anticonvulsants and antibiotics.

DJ Back, SF Grimmer, MLE Orme… - British journal of …, 1988 - Wiley Online Library
1. We have searched the adverse reactions register for the years 1968‐ 84 in an attempt to
evaluate data relating to reported pregnancies in women on oral contraceptive steroids (OCS…

Clinical pharmacokinetics of oral contraceptive steroids

MLE Orme, DJ Back, AM Breckenridge - Clinical pharmacokinetics, 1983 - Springer
Oral contraceptive steroids are of 2 types: oestrogens, of which ethinyloestradiol is the most
important, and progestagens, of which levonorgestrel and norethisterone are the most …

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

VA Eagling, DJ Back, MG Barry - British journal of clinical …, 1997 - Wiley Online Library
Aims To compare the inhibitory potential of the HIV protease inhibitors saquinavir, ritonavir
and indinavir against CYP1A2, CYP2C9, CYP2E1 and CYP3A4 catalysed metabolic …

Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes

VA Eagling, JF Tjia, DJ Back - British journal of clinical …, 1998 - Wiley Online Library
Aims Chemical inhibitors of cytochrome P450 (CYP) are a useful tool in defining the role of
individual CYPs involved in drug metabolism. The aim of the present study was to evaluate …

The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.

…, DJ Chadwick, C Martin, J Tjia, DJ Back… - British journal of …, 1990 - Wiley Online Library
Patients taking oral contraceptive steroids (OCS) are known to suffer contraceptive failure
while taking anticonvulsants such as phenobarbitone, phenytoin and carbamazepine. We …

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

…, CE James, S Gibbons, PG Bray, DJ Back… - Pharmacogenetics …, 2010 - journals.lww.com
Objective OATP1B1 and OATP1B3 are major hepatic drug transporters whilst OATP1A2 is
mainly located in the brain but is also located in liver and several other organs. These …

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

…, SH Khoo, D Egan, DJ Back… - Journal of …, 2008 - academic.oup.com
Objectives The aim of this study was to investigate the frequency of CYP2B6 polymorphisms
(according to ethnicity) and the influence of heterozygosity and homozygosity on plasma …